EMA HMPC Launches Call for Data on Maydis Stigma (Zea mays L.) EMA HMPC Launches Call for Data on Maydis Stigma (Zea mays L.) The European Medicines Agency’s (EMA) Committee on Herbal... EMA HMPC Launches Call for Data on Maydis Stigma (Zea mays L.)
Updated EMA Q&A on Consultation Procedure to EMA by Notified Bodies on Ancillary Medicinal Substance / Ancillary Human Blood Derivative Incorporated in a Medical Device Updated EMA Q&A on Consultation Procedure to EMA by Notified Bodies on Ancillary Medicinal Substance / Ancillary Human Blood Derivative... Updated EMA Q&A on Consultation Procedure to EMA by Notified Bodies on Ancillary Medicinal Substance / Ancillary Human Blood Derivative Incorporated in a Medical Device
CMDh July 2023 Meeting – Report CMDh July 2023 Meeting – Report The Co-ordination group for Mutual recognition and Decentralised procedures – human (CMDh) has published... CMDh July 2023 Meeting – Report
MHRA Renewing Marketing Authorisations for Medicines – Guidance Updated MHRA Renewing Marketing Authorisations for Medicines – Guidance Updated MHRA has updated their guidance on renewal applications to... MHRA Renewing Marketing Authorisations for Medicines – Guidance Updated
Nitrosamines – Revised Q&A for Marketing Authorisation Holders/Applicants Nitrosamines – Revised Q&A for Marketing Authorisation Holders/Applicants The revised EMA/HMA Questions and answers for marketing authorisation holders/applicants on the... Nitrosamines – Revised Q&A for Marketing Authorisation Holders/Applicants
Office for Life Sciences Bulletin – 24 July 2023 Office for Life Sciences Bulletin – 24 July 2023 The Office for Life Sciences (OLS) is a joint unit between... Office for Life Sciences Bulletin – 24 July 2023
Windsor Framework Labelling and Packaging Guidance Published Windsor Framework Labelling and Packaging Guidance Published MHRA has published the ‘Windsor Framework Labelling & Packaging Guidance’ on the MHRA... Windsor Framework Labelling and Packaging Guidance Published
MHRA Drug Safety Update – July 2023 MHRA July 2023 Drug Safety Update The MHRA July 2023 Drug Safety Update contains information on hyoscine hydrobromide patches and... MHRA Drug Safety Update – July 2023
MHRA Public Consultation on Reclassification of Opioid-Containing Cough Medicine to a Prescription-Only Medicine MHRA Public Consultation on Reclassification of Aquiette 2.5mg Tablets (Oxybutynin Hydrochloride) to a Pharmacy Medicine MHRA has launched a... MHRA Public Consultation on Reclassification of Opioid-Containing Cough Medicine to a Prescription-Only Medicine
MHRA Annual Report and Accounts 2022 – 2023 Published Share: Share via Facebook... MHRA Annual Report and Accounts 2022 – 2023 Published
MHRA Consultation on Revised International Council for Harmonisation (ICH) on Good Clinical Practice (GCP) Guidelines MHRA Consultation on Revised International Council for Harmonisation (ICH) on Good Clinical Practice (GCP) Guidelines MHRA has launched a ... MHRA Consultation on Revised International Council for Harmonisation (ICH) on Good Clinical Practice (GCP) Guidelines
MHRA Performance Data for Assessment of Clinical Trials and Established Medicines MHRA Performance Data for Assessment of Clinical Trials and Established Medicines MHRA has published information on current performance of regulatory... MHRA Performance Data for Assessment of Clinical Trials and Established Medicines
